Moomoo AI 已提取核心訊息
Clearmind Medicine Inc., a pharmaceutical company specializing in the development of psychedelic medicines, has filed a post-effective amendment to Form F-1 on Form F-3 with the Securities and Exchange Commission (SEC) on January 18, 2024. This filing is intended to convert two earlier registration statements into registration statements on Form F-3 and to file a combined prospectus. The registration statements in question were initially declared effective by the SEC on April 3, 2023, and September 14, 2023, respectively, and relate to the offering and sale of up to 1,047,384 Common Shares issuable upon the exercise of warrants. These shares are currently traded on the Nasdaq Capital Market under the symbol 'CMND.' The company has stated that the proceeds from the exercise of the warrants will be used for working capital, general corporate purposes, and potential strategic acquisitions.
Clearmind Medicine Inc., a pharmaceutical company specializing in the development of psychedelic medicines, has filed a post-effective amendment to Form F-1 on Form F-3 with the Securities and Exchange Commission (SEC) on January 18, 2024. This filing is intended to convert two earlier registration statements into registration statements on Form F-3 and to file a combined prospectus. The registration statements in question were initially declared effective by the SEC on April 3, 2023, and September 14, 2023, respectively, and relate to the offering and sale of up to 1,047,384 Common Shares issuable upon the exercise of warrants. These shares are currently traded on the Nasdaq Capital Market under the symbol 'CMND.' The company has stated that the proceeds from the exercise of the warrants will be used for working capital, general corporate purposes, and potential strategic acquisitions.
專門從事迷幻藥物開發的製藥公司Clearmind Medicine Inc. 已於2024年1月18日向美國證券交易委員會（SEC）提交了對F-3表格F-1的生效後修正案。該文件旨在將之前的兩份註冊聲明轉換爲F-3表格上的註冊聲明，並提交合並的招股說明書。有關注冊聲明最初由美國證券交易委員會分別於2023年4月3日和2023年9月14日宣佈生效，涉及發行和出售最多1,047,384股可在行使認股權證時發行的普通股。這些股票目前在納斯達克資本市場上交易，股票代碼爲 “CMND”。該公司表示，行使認股權證的收益將用於營運資金、一般公司用途和潛在的戰略收購。
專門從事迷幻藥物開發的製藥公司Clearmind Medicine Inc. 已於2024年1月18日向美國證券交易委員會（SEC）提交了對F-3表格F-1的生效後修正案。該文件旨在將之前的兩份註冊聲明轉換爲F-3表格上的註冊聲明，並提交合並的招股說明書。有關注冊聲明最初由美國證券交易委員會分別於2023年4月3日和2023年9月14日宣佈生效，涉及發行和出售最多1,047,384股可在行使認股權證時發行的普通股。這些股票目前在納斯達克資本市場上交易，股票代碼爲 “CMND”。該公司表示，行使認股權證的收益將用於營運資金、一般公司用途和潛在的戰略收購。
有用
沒用